Abstract:Dry eye disease (DED) is a multifactorial disorder characterized by loss of tear film homeostasis with an estimated worldwide prevalence of 5% to 50%. In DED, dysfunction of the ocular structures that create and regulate the tear film components—including the lacrimal glands, meibomian glands, cornea, and conjunctiva—causes a qualitative and/or quantitative tear deficiency with resultant tear film instability and hyperosmolarity. This initiates a vicious cycle of ocular surface inflammation and damage that may ultimately impair the quality of life and vision of affected patients. Many factors can contribute to the development of DED, including ocular and systemic diseases, topical and systemic medications, and environmental conditions. Because DED is a chronic disorder, treatment is most often long term and may utilize both pharmacologic and nonpharmacologic interventions to address all etiologic components. The long-term management of DED can be challenging and most often should involve eye care specialist referral. However, primary care clinicians (PCCs) are often the first points of contact for patients with DED and importantly provide initial diagnosis and preliminary patient education about the disease process. Consideration of DED is also vital for the practice of various specialties due to the large number of comorbidities and medications that can contribute to DED pathogenesis and progression. Therefore, it is important that PCCs and clinical specialists be aware of the etiology of DED and its available therapeutic options. This manuscript provides an overview of DED pathophysiology and treatment and discusses specific considerations regarding DED management for PCCs and clinical specialists. Successful management of dry eye disease often requires the use of various pharmacologic and/or nonpharmacologic therapies, as well as environmental and lifestyle modifications, to mitigate the underlying etiologies and restore tear film homeostasis. Primary care clinicians play an essential role in dry eye disease management by establishing a diagnosis, educating patients about the disorder, and providing referrals to eye care specialists for initiation of specialized treatment and long-term follow-up. Primary care clinicians and clinical specialists should consider prescribing medications with fewer ocular surface effects whenever possible in patients at risk for or with existing dry eye disease.

Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application

Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials

Dry Eye Disease: Focus on Prescription Therapy

Formulation Considerations for the Management of Dry Eye Disease

Newer approaches to dry eye therapy: Nanotechnology, regenerative medicine, and tissue engineering

Alternative therapies for dry eye disease

Navigating Dry Eye Research: A Comprehensive Review of Etiology, Clinical Trials, Patents, and Recent Advancements

Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review

Device-based therapies as a boost of conventional treatment in dry eye disease

Advances in dry eye disease treatment

Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine

THE ANALYSIS STUDY OF INTERVENTIONS FOR DRY EYES: A COMPREHENSIVE SYSTEMATIC REVIEW

Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists

Dry Eye Disease: Consideration for Women's Health

Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review

Recent progress of nanomedicine in managing dry eye disease

Exploring novel pharmacological trends: Natural compounds in dry eye disease management

Novel treatments for dry eye syndrome